Insight Molecular Diagnostics Inc. (IMDX) Free cash flow 2016–2025
Insight Molecular Diagnostics Inc. (IMDX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$25.4MFY2025 · since FY2016: -$7.6M → -$25.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$25.4M | -19.6% |
| FY2024 | -$21.2M | +10.2% |
| FY2023 | -$23.6M | +52.7% |
| FY2022 | -$49.9M | -30.7% |
| FY2021 | -$38.2M | -40.4% |
| FY2020 | -$27.2M | -31.9% |
| FY2019 | -$20.6M | -76.7% |
| FY2018 | -$11.7M | +13.3% |
| FY2017 | -$13.5M | -76.7% |
| FY2016 | -$7.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IMDX financial trends
IMDX RevenueIMDX Net incomeIMDX Net marginIMDX Gross profitIMDX Gross marginIMDX Operating incomeIMDX Operating marginIMDX Operating cash flowIMDX Capital expendituresIMDX Return on equityIMDX Stock buybacksIMDX Dividends paidIMDX Total assetsIMDX Total liabilitiesIMDX Shareholders’ equityIMDX overview →